Liver lipid content is reduced in rat given 7-day administration of angiotensin II

Area of Science:

• Cardiovascular Research
• Metabolic Syndrome
• Hepatology

Background:

• The renin-angiotensin system's role in hepatic steatosis and insulin resistance is increasingly recognized.
• Previous studies indicated angiotensin II promotes triglyceride accumulation in renal and cardiac cells.

Purpose of the Study:

• To investigate the long-term effects of angiotensin II on liver lipid content in rats.
• To elucidate the specific mechanisms and receptor pathways involved in angiotensin II-induced liver lipid changes.

Main Methods:

• Rats received continuous angiotensin II infusion for 7 days via osmotic minipump.
• Concurrent administration of hydralazine or losartan was used to block specific pathways.
• Liver triglyceride content and lipid droplet accumulation were quantified using biochemical assays and Oil Red O staining.
• Gene expression analysis of key metabolic regulators (AMPK, PPAR-α) and lipogenic/β-oxidation pathways was performed.

Main Results:

• Angiotensin II significantly reduced liver triglyceride content and Oil Red O-stainable lipid droplets.
• These effects were completely blocked by losartan, indicating AT1 receptor dependency.
• Angiotensin II decreased AMP-activated protein kinase activity and mRNA expression of PPAR-α and β-oxidation genes.
• Lipogenesis gene expression remained unaffected, suggesting a mechanism independent of increased fat synthesis.

Conclusions:

• Long-term angiotensin II administration reduces hepatic steatosis in rats via an AT1 receptor-dependent mechanism.
• The reduction in liver fat is associated with decreased expression of genes involved in fatty acid oxidation and AMPK activity, not altered lipogenesis.
• These findings highlight a novel role for the renin-angiotensin system in regulating liver fat metabolism.